Sign inJoin free

Watch / Small Cap

Fergie's 'crazy' value offers | Chimeric's jump on positive trial | Omega's big gas discovery

23 Oct 202330:12

Fergie's 'crazy' value offers | Chimeric's jump on positive trial | Omega's big gas discovery

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Dean Fergie from Cyan Investment Management discussed the prolonged underperformance of small caps over the past two years, highlighting that this segment is currently presenting significant value opportunities. He drew comparisons with past market cycles to emphasise the extent of current undervaluation. Despite a generally pessimistic market sentiment and challenges like interest rate rises, Fergie argued for a fundamental, sensible investment approach focused on long-term value. He presented specific examples of undervalued companies, emphasising the importance of looking beyond short-term market conditions and focusing on inherent value and financial stability. Fergie urged investors to conduct thorough research and adopt a longer-term perspective to capitalise on the potential for strong returns in the small cap sector.

Jennifer Chow, Managing Director at Chimeric Therapeutics (CHM) discussed the positive interim data from a clinical trial for late stage brain cancer treatment. She highlighted the use of cell therapy, specifically engineered cells, in treating recurrent glioblastoma. The trial showed promising results, with 55% of patients achieving disease control and extended survival rates, including cases of 19 and 14+ months. Chow emphasised the importance of quality of life and safety in the trials. She outlined the next steps for the company, including an A1B expansion cohort, potential regulatory discussions for phase two, and emphasised their cash management strategies and partnerships with institutions. The team, mostly based in the U.S., has extensive experience in cell therapy, providing valuable connections for clinical development. Chow stressed the importance of focusing on clinical progress to realize value and satisfy investors.

Trevor Brown, special adviser for Omega Oil and Gas (OMA) discussed a major gas discovery in the Taroom trough, QLD, affirming its significant potential addition to the East Coast gas market. The 2C contingent resources were verified by Netherland Sewell Associates Incorporated at 1.73 TCF. Omega Oil and Gas plans to test the producibility through a horizontal well and stimulation program, with results expected in 12 months. The company’s strategic positioning benefits from proximity to established infrastructure and skilled personnel, targeting the Bowen Basin for future gas supply. Trevor also highlighted their recent successful capital raise of over $21 million, securing full funding for the upcoming drilling program. Omega Oil is backed by two large strategic investors, Illela and Tri Star Group, bringing capital and industry expertise.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy